BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 24378577)

  • 1. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
    Buendia JA; Bramuglia G; Staatz CE
    Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
    Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
    Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
    Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
    Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
    Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.
    Rojas LE; Herrero MJ; Bosó V; García-Eliz M; Poveda JL; Librero J; Aliño SF
    Pharmacogenet Genomics; 2013 Oct; 23(10):509-17. PubMed ID: 23873120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
    Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
    Tang HL; Xie HG; Yao Y; Hu YF
    Pharmacogenet Genomics; 2011 Nov; 21(11):713-20. PubMed ID: 21886016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
    Gómez-Bravo MA; Apellaniz-Ruiz M; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Bilbao I; Alamo JM; Millán O; Brunet M; Rodríguez-Antona C
    Pharmacogenet Genomics; 2018 Feb; 28(2):41-48. PubMed ID: 29256966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
    Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
    Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.
    Alvarez-Elías AC; García-Roca P; Velásquez-Jones L; Valverde S; Varela-Fascinetto G; Medeiros M
    Transplant Proc; 2016 Mar; 48(2):631-4. PubMed ID: 27110018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism.
    Durand P; Debray D; Kolaci M; Bouligand J; Furlan V; Fabre M; Letierce A; Verstuyft C; Becquemont L
    Pharmacogenomics; 2013 Jul; 14(9):1017-25. PubMed ID: 23837476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recipient ABCB1, donor and recipient CYP3A5 genotypes influence tacrolimus pharmacokinetics in liver transplant cases.
    Naushad SM; Pavani A; Rupasree Y; Hussain T; Alrokayan SA; Kutala VK
    Pharmacol Rep; 2019 Jun; 71(3):385-392. PubMed ID: 31003147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
    Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
    Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.